ライフサイエンスコーパス: prostate-specific antigen

1 amino acids sequence (HSSKLQL) specific for Prostate Specific Antigen.

2 ction and prostate cancer together with KLK3/prostate-specific antigen.

3 pairs that are associated with pre-operative prostate-specific antigen.

4 te-specific antigen < 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL), LDR brachyth

5 /X M0, 25% N0M0; 94% newly diagnosed; median prostate-specific antigen, 66 ng/mL.

6 men (mean age, 62 years [range, 40-76]; mean prostate-specific antigen, 8.2 ng/mL [8.2 mug/L] [range,

7 ould improve specificity over measurement of prostate-specific antigen alone for detecting cancer wit

8 been functionalized with antibodies to bind prostate specific antigen and immunoglobulin (IgG).

9 cancer screening currently consists of serum prostate-specific antigen and digital rectal examination

10 o biopsy, adjusting for age and longitudinal prostate-specific antigen and digital rectal examination

11 ide, 25-hydroxyvitamin D) and 2 nonhormones (prostate-specific antigen and ferritin).

12 Prostate-specific antigen and prostate-specific membrane

13 ning for AR and the androgen-regulated genes prostate-specific antigen and TMPRSS2 was strongly suppr

14 variate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal e

15 roendocrine markers, p63, androgen receptor, prostate specific antigen, and chromogranin A, respectiv

16 rkers, including human alpha-thrombin, human prostate specific antigen, and human epidermal growth fa

17 , opioid analgesic use, albumin, hemoglobin, prostate-specific antigen, and alkaline phosphatase.

18 lation with progression-free survival (PFS), prostate-specific antigen, and markers of bone turnover.

19 ety; progression-free survival (PFS); tumor, prostate-specific antigen, and pain response; pharmacoki

20 ical distress, cancer-specific distress, and prostate-specific antigen anxiety.

21 Creatinine estimation and prostate-specific antigen are recommended in selected gr

22 the US Preventive Services Task Force giving prostate specific antigen-based prostate cancer screenin

23 from a backlash against overdiagnosis due to prostate specific antigen-based screening efforts and ar

24 R, 1.07; P = .80), respectively; and 10-year prostate-specific antigen-based recurrence cumulative in

25 Findings from recent trials on prostate-specific antigen-based screening suggest that s

26 ery in these two cohorts, independent of the prostate-specific antigen biomarker or Gleason grade, a

27 d indices and explored their relation to the prostate-specific antigen blood value, the bone scan ind

28 SUVs and lesion number were correlated with prostate-specific antigen change, clinical impression, a

29 f seminal vesicle involvement less than 30%, prostate-specific antigen concentration less than 30 ng/

30 iables including Gleason score, preoperative prostate-specific antigen concentration, seminal vesicle

31 ad not had radiotherapy using Gleason score, prostate-specific antigen concentration, surgical margin

32 e and that anti-GRP78 AutoAb levels parallel prostate-specific antigen concentrations in patient-deri

33 Serum prostate-specific antigen concentrations showed signific

34 Men with prostate-specific antigen concentrations up to 15 ng/mL,

35 acy was biochemical response as defined by a prostate-specific antigen decline >/= 50% from baseline

36 Both patients experienced a prostate-specific antigen decline to below the measurabl

37 At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, bu

38 Prostate-specific antigen declines at 12 weeks (>/= 50%

39 each additional year; 95% CI, 1.01 to 1.06), prostate-specific antigen density (HR, 1.21 per 0.1 unit

40 Factors associated with intervention were prostate-specific antigen density (HR, 1.38 per 0.1 unit

41 used to attribute these risk categories are prostate specific antigen, digital rectal examination, t

42 cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination pro

43 C at high risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but

44 Transmission SPR measurements of free prostate specific antigen (f-PSA), which is similar in s

45 etection of a cancer protein biomarker, free prostate specific antigen (f-PSA).

46 were performed in 36 subjects with a rising prostate-specific antigen for known (n = 15) or suspecte

47 device and tested for the detection of free Prostate Specific Antigen (fPSA).

48 r and had received no previous chemotherapy; prostate-specific antigen greater than 5 ng/mL; and a Ka

49 o July 31, 2007, due to biochemical failure (prostate-specific antigen > 0.2 mg/mL) during androgen-d

50 ratio, 2.53; 95% CI, 1.41-4.53; P = 0.002), prostate-specific antigen (hazard ratio, 1.03; 95% CI, 1

51 metry to demonstrate nanomolar detection for prostate specific antigen in aqueous buffer and picomola

52 tor, aedemonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and an

53 We demonstrate femtomolar-level detection of prostate-specific antigen in biological fluids, as well

54 ction of 10 pM was achieved for detection of prostate-specific antigen in buffer and diluted serum.

55 activates and complements chymotryptic KLK3 (prostate-specific antigen) in cleaving seminal clotting

56 n LNCaP cell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression.

57 0 ng/mL, and 22 with biochemical recurrence (prostate-specific antigen level > 0.20 ng/mL after nadir

58 stage </=T2a, biopsy Gleason score </=6, and prostate-specific antigen level </=10 ng/mL), high risk

59 = 0.0173) and a borderline association with prostate-specific antigen level (P = 0.0458).

60 ing hemoglobin level (r = -0.521, P < .001), prostate-specific antigen level (r = 0.556, P < .001), l

61 ), Gleason score (rho, range, 0.03 to 0.20), prostate-specific antigen level (rho, range, -0.07 to 0.

62 changes in tDV and best percentage change in prostate-specific antigen level and circulating tumor ce

63 st and logistic regression; correlation with prostate-specific antigen level and circulating tumor ce

64 Prostate-specific antigen level at the time of PET corre

65 asis, 17 with a persistent postprostatectomy prostate-specific antigen level greater than 0.20 ng/mL,

66 cancer is suspected when an increase in the prostate-specific antigen level is detected after radica

67 tile range [IQR], 61-72) years, median (IQR) prostate-specific antigen level of 43 (18-88) ng/mL.

68 ; they had Gleason scores of 7-10 and a mean prostate-specific antigen level of 7.8 mug/L (range, 5.4

69 Eleven patients with a prostate-specific antigen level of at least 4 ng/mL (4 m

70 The rate of a prostate-specific antigen level of less than 0.2 ng per

71 e prostate cancer, particularly those with a prostate-specific antigen level of less than 10 ng/mL an

72 .1, or as a reduction of at least 50% in the prostate-specific antigen level or a confirmed reduction

73 alliative radiotherapy, and the median (IQR) prostate-specific antigen level was 146 (51-354).

74 Function (IIEF) score, prostate volume, and prostate-specific antigen level were assessed for up to

75 ical stage T1c/T2a; Gleason score, </=6; and prostate-specific antigen level, <10 ng/mL) or breast ca

76 66-74 y) with biochemical recurrence (median prostate-specific antigen level, 1.31 ng/mL; interquarti

77 with prostate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL; range, 0.25-29

78 for standard clinical parameters (age, serum prostate-specific antigen level, alkaline phosphatase, u

79 of a visit to the urologist, measurement of prostate-specific antigen level, and multiparametric MR

80 Control patients (n = 134) matched for age, prostate-specific antigen level, and stage were selected

81 Hypofractionation, pretreatment prostate-specific antigen level, Gleason score, and clin

82 The prostate-specific antigen level, IPSS, and SHIM score be

83 At multivariate analysis, prostate-specific antigen level, primary Gleason grade g

84 Recurrence was defined as two prostate-specific antigen levels >/= 0.2 ng/mL or any sa

85 gital rectal examination results or elevated prostate-specific antigen levels (age groups: 41-50 year

86 undance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patie

87 ed to delineate the relationship between the prostate-specific antigen levels and the diffusion param

88 obtained by applying mathematical models to prostate-specific antigen levels as the representation o

89 Hematocrit and prostate-specific antigen levels increased more in testo

90 stage cT1-2, localized prostate cancer, with prostate-specific antigen levels less than 50 ng/mL, and

91 A decrease in prostate-specific antigen levels was noted in 45 of 56 p

92 ematologic status, renal function, and serum prostate-specific antigen levels were documented before

93 In 101 biopsy-naive patients with elevated prostate-specific antigen levels who underwent multipara

94 ratify survival among patients with elevated prostate-specific antigen levels.

95 detection rates even in the presence of low prostate-specific antigen levels.

96 ntermediate risk prostate cancer (Gleason 7, prostate-specific antigen < 10 ng/mL or Gleason 6, prost

97 All patients had a rising level of prostate-specific antigen (mean +/- SD, 13.5 +/- 11.5) a

98 llowed (ie, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal

99 or growth was monitored through weekly serum prostate-specific antigen measurements, and mice with re

100 ical failure was defined with the use of the prostate-specific antigen nadir + 2-ng/mL definition), f

101 nfirmed T1b-T3a, N0, M0 prostate cancer with prostate specific antigen of less than 50 ng/mL.

102 k Gleason 7 prostate cancers, independent of prostate-specific antigen or nomogram score.

103 ne alkaline phosphatase (P = 0.0014) but not prostate-specific antigen (P = 0.47).

104 associations included the following: SUV and prostate-specific antigen percentage change at 6 mo (P =

105 nts in all key secondary end points: time to prostate-specific antigen progression (HR, 0.19; 95% CI,

106 ily for asymptomatic, local, or biochemical (prostate-specific antigen) progression.

107 Presence of prostate-specific antigen (proxy for recent sex) and bei

108 range) was decorated with antibodies against prostate specific antigen (PSA) and prostate specific me

109 For protein biomarker prostate specific antigen (PSA) assay, we immobilized ca

110 ta-MIP) with FETs for sensitive detection of prostate specific antigen (PSA) at clinically relevant c

111 immunosensor was developed for detection of prostate specific antigen (PSA) based on immobilization

112 was designed to utilize for the detection of prostate specific antigen (PSA) based on three different

113 Refractive index-based sensing of prostate specific antigen (PSA) both in buffer and serum

114 n in human serum of as low as 25 pg/ml total prostate specific antigen (PSA) during 30-min assay.

115 risk SNPs have also been found to influence prostate specific antigen (PSA) expression levels and po

116 We demonstrate how prostate specific antigen (PSA) expression varies over s

117 exhibited real-time reversible detection of prostate specific antigen (PSA) from 1 to 1,000 nM in 10

118 sent a MoS2 biosensor to electrically detect prostate specific antigen (PSA) in a highly sensitive an

119 trated label-free and real-time detection of prostate specific antigen (PSA) in human serum using sil

120 rescein (6-FAM) capable of rapidly capturing prostate specific antigen (PSA) in human serum, cost-eff

121 titation of a surrogate peptide (SVILLGR) of prostate specific antigen (PSA) in multiple serum sample

122 ochemical aptasensor to detect the biomarker prostate specific antigen (PSA) in serum.

123 Prostate specific antigen (PSA) is a widely used serum m

124 er incidence of metastatic events and higher prostate specific antigen (PSA) levels, with similar tre

125 Highly sensitive and label free detection of prostate specific antigen (PSA) still remains a challeng

126 The development of the prostate specific antigen (PSA) test, and a continuing d

127 unting single molecules of the cancer marker prostate specific antigen (PSA) using photon-upconversio

128 ed DNA aptamer with established affinity for prostate specific antigen (PSA) was complexed with PSA p

129 tive electrochemical sensor for detection of prostate specific antigen (PSA) was developed using surf

130 pidermal growth factor receptor 2 (HER2) and prostate specific antigen (PSA), and is also capable of

131 the effects of soy isoflavone consumption on prostate specific antigen (PSA), hormone levels, total c

132 kers, human chorionic gonadotropin (hCG) and prostate specific antigen (PSA), in serum samples.

133 Prostate cancer biomarker proteins, prostate specific antigen (PSA), prostate specific membr

134 The proteins are prostate specific antigen (PSA), prostate specific membr

135 antitative sandwich immunoassay detection of prostate specific antigen (PSA).

136 dermal growth factor receptor-2 (HER-2), and prostate specific antigen (PSA).

137 -free aptasensor to make direct detection of prostate specific antigen (PSA, a biomarker of prostate

138 tal of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) >/= 10 ng/mL or Gleason

139 esistant prostate cancer (CRPC) and baseline prostate-specific antigen (PSA) >/= 8.0 ng/mL and/or PSA

140 All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL;

141 ive Services Task Force (USPSTF) discouraged prostate-specific antigen (PSA) -based prostate cancer s

142 ters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT.

143 e radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatect

144 on the therapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase

145 We determine kon and koff for prostate-specific antigen (PSA) and compare to gold-stan

146 Serum prostate-specific antigen (PSA) and Expanded Prostate In

147 ncluding high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, a

148 We determine kon and koff for prostate-specific antigen (PSA) and make a comparison to

149 Prostate-specific antigen (PSA) and MRI changes may be u

150 ced prostate MR imaging in men with elevated prostate-specific antigen (PSA) and negative transrectal

151 urpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in

152 ing tool, to diagnose prostate cancer (PCa): prostate-specific antigen (PSA) and spondin-2 (SPON2).

153 )S significantly repressed the expression of prostate-specific antigen (PSA) and TMPRSS2, two AR-targ

154 The prostate-specific antigen (PSA) assays currently employe

155 ent of the gold content allowed detection of Prostate-Specific Antigen (PSA) at the low attog mL(-1)

156 a strong association between CHD1 deletion, prostate-specific antigen (PSA) biochemical failure (P =

157 pplied stratification systems use presenting prostate-specific antigen (PSA) concentration, biopsy Gl

158 ease-specific quality of life, health worry, prostate-specific antigen (PSA) concern, and outlook on

159 Men who did not achieve >/= 30% prostate-specific antigen (PSA) decline by cycle 4 (C4)

160 Intervention was offered for a prostate-specific antigen (PSA) doubling time of less th

161 The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less th

162 noma, with strong androgen receptor (AR) and prostate-specific antigen (PSA) expression.

163 gen) PET/CT is increasingly used in men with prostate-specific antigen (PSA) failure after radical pr

164 controlled trials (RCTs) relating to reduced prostate-specific antigen (PSA) failure, yet whether thi

165 Surveillance was performed with prostate-specific antigen (PSA) follow-up every 3 months

166 For the measurements of prostate-specific antigen (PSA) in 50% serum using the p

167 ascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early

168 tibody was employed for the determination of prostate-specific antigen (PSA) in human serum samples.

169 free, and ultrahigh-sensitivity detection of prostate-specific antigen (PSA) in human serum.

170 immunosorbent assay (ELISA) measurements for prostate-specific antigen (PSA) in selected patient sera

171 Prostate-specific antigen (PSA) is a biomarker for monit

172 Prostate-specific antigen (PSA) kinetics, and more speci

173 , renal scintigraphy, clinical data, and the prostate-specific antigen (PSA) level at baseline and 8

174 Measure prostate-specific antigen (PSA) level every 6 to 12 mont

175 deprivation therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4.0 ng

176 Prostate-specific antigen (PSA) level in midlife predict

177 ancer, a performance status of 0 to 2, and a prostate-specific antigen (PSA) level of 5 ng per millil

178 Median prostate-specific antigen (PSA) level was 1.99 ng/mL (ra

179 His prostate-specific antigen (PSA) level was 7.1 ng/mL.

180 The 24-hour post-PAE prostate-specific antigen (PSA) level was registered in

181 ADT, with complete datasets for RT, surgery, prostate-specific antigen (PSA) level, Gleason score, an

182 rior negative biopsy findings with increased prostate-specific antigen (PSA) level, or (c) had a prio

183 fine patient characteristics, including age, prostate-specific antigen (PSA) level, PSA density, race

184 ed by a persistently or recurrently elevated prostate-specific antigen (PSA) level.

185 ectal examination (DRE) results but elevated prostate-specific antigen (PSA) levels (4-20 ng/mL) who

186 Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were

187 (68)Ga-PSMA I&T PET/CT because of increasing prostate-specific antigen (PSA) levels after radical pro

188 interrogated irrespective of Gleason grade, prostate-specific antigen (PSA) levels and pathological

189 Joint statistical model of longitudinal prostate-specific antigen (PSA) levels and risks for bio

190 techniques have a low detection rate at the prostate-specific antigen (PSA) levels at which targeted

191 Prostate-specific antigen (PSA) levels have been used fo

192 and correlated its diagnostic accuracy with prostate-specific antigen (PSA) levels in prostate cance

193 ay with biopsy outcomes in 499 patients with prostate-specific antigen (PSA) levels of 2 to 20 ng/mL.

194 n-dependent LNCaP PCa cells increased AR and prostate-specific antigen (PSA) levels, stimulated growt

195 urgery and continued for up to 2 years, with prostate-specific antigen (PSA) measurements made at 2-m

196 from prostate cancer patients: both CTCs and prostate-specific antigen (PSA) mRNA sequences were dete

197 ad non-castration levels of testosterone and prostate-specific antigen (PSA) of 2 ng/mL or greater at

198 One hundred eighteen patients with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range, 2.2

199 prostate cancer or T1-2 disease with either prostate-specific antigen (PSA) of more than 40 mug/L or

200 Patients were referred for elevated level of prostate-specific antigen (PSA) or abnormal digital rect

201 tissue response (59% vs. 5%), the time until prostate-specific antigen (PSA) progression (hazard rati

202 ent continued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise,

203 Gleason grade, advanced pT stage, and early prostate-specific antigen (PSA) recurrence in all cancer

204 ta, week 13 circulating tumor cell (CTC) and prostate-specific antigen (PSA) response end points in f

205 Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and w

206 een AR-V7 status (positive vs. negative) and prostate-specific antigen (PSA) response rates (the prim

207 luated associations between AR-V7 status and prostate-specific antigen (PSA) response rates, PSA prog

208 Main Outcomes and Measures: Prostate-specific antigen (PSA) response, time receiving

209 We examined >/= 50% prostate-specific antigen (PSA) responses, PSA progressi

210 progression on enzalutamide with a continued prostate-specific antigen (PSA) rise after enzalutamide

211 2012, US guidelines have recommended against prostate-specific antigen (PSA) screening for prostate c

212 Prostate-specific antigen (PSA) screening for prostate c

213 Prostate-specific antigen (PSA) screening has reduced th

214 Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversi

215 ecently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies out

216 The benefits of screening with the prostate-specific antigen (PSA) test are outweighed by t

217 Prostate cancer screening with the prostate-specific antigen (PSA) test remains controversi

218 A serum prostate-specific antigen (PSA) test was 12.4 ng/mL.

219 d a specialist nurse appointment for a serum prostate-specific antigen (PSA) test.

220 Current prostate-specific antigen (PSA) testing has resulted in

221 core age group (55-69 years), which assesses prostate-specific antigen (PSA) testing in eight Europea

222 Prostate-specific antigen (PSA) testing provides signifi

223 ents for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertai

224 -negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or

225 eveloped for ultrasensitive immunosensing of prostate-specific antigen (PSA) tumor marker.

226 The median prostate-specific antigen (PSA) value was 1.0 ng/mL (mea

227 Interestingly, on considering prostate-specific antigen (PSA) value, (64)CuCl2 PET/CT

228 uperior to standard-of-care imaging at serum prostate-specific antigen (PSA) values low enough to aff

229 Prostate-specific antigen (PSA) values were >0.2 ng/mL a

230 Afterward, data were compared with current prostate-specific antigen (PSA) values, Gleason score (G

231 The prostate-specific antigen (PSA) was 114 ng/mL; he had no

232 Prostate-specific antigen (PSA) was determined every 4 w

233 Antibody arrays for prostate-specific antigen (PSA) were printed, and a sand

234 Prostate-specific antigen (PSA) widely used in clinics h

235 o 21 were evaluated for association with OS, prostate-specific antigen (PSA), and RECIST response usi

236 g tumor cells (CTCs), bone biomarkers, serum prostate-specific antigen (PSA), and symptomatic skeleta

237 rochemical immunosensor for the detection of prostate-specific antigen (PSA), based on covalently imm

238 cer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as

239 rker for prostate adenocarcinoma (PC), serum prostate-specific antigen (PSA), greatly overestimates P

240 r Prevention Trial (n = 5,986), we evaluated prostate-specific antigen (PSA), International Prostate

241 -related peptidase 3 (KLK3), which codes for prostate-specific antigen (PSA), is a well-known AR-regu

242 n the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a

243 ve been evaluated in multiple studies: %free prostate-specific antigen (PSA), PSA velocity, PSA doubl

244 s Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this

245 To examine whether the use of prostate-specific antigen (PSA)-based screening in patie

246 n of rabbit immunoglobulin G (IgG) and human-prostate-specific antigen (PSA).

247 sitive margins, and detectable postoperative prostate-specific antigen (PSA).

248 whose F protein is cleavable exclusively by prostate-specific antigen (PSA).

249 r growth can be estimated by measuring serum prostate-specific antigen (PSA, a PCa biomarker in blood

250 and synaptophysin while concurrently lacking prostate-specific antigen (PSA, KLK3) expression.

251 t an absolute 20% difference in undetectable prostate-specific antigen (PSA; </= 0.2 ng/mL) rate at 2

252 e cancer (T1 to 2a, Gleason score </= 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to

253 e the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5

254 Efficacy measures (time to prostate-specific antigen [PSA] progression and time to

255 ) (clinical stage, T1c; Gleason score, </=6; prostate-specific antigen [PSA], <10 ng/mL; PSA density

256 on-free survival [rPFS], >/= 50% decrease of prostate-specific antigen [PSA50], and pain response at

257 sy-proven PCa (5 with primary PCa and 5 with prostate-specific antigen recurrence after radical prost

258 ssion was correlated with Gleason scores and prostate-specific antigen recurrence.

259 tients (mean age, 68 y; range, 44-87 y) with prostate-specific antigen relapse (mean prostate-specifi

260 was significantly associated with a reduced prostate-specific antigen relapse-free survival.

261 cause screening for prostate cancer based on prostate-specific antigen remains controversial due to t

262 .001); proportion of patients with a >/= 50% prostate-specific antigen response (81% v 31%; P < .001)

263 Prostate-specific antigen response and hematologic toxic

264 reasonable response, mainly as defined by a prostate-specific antigen response of more than 50%, com

265 Main Outcomes and Measures: Prostate-specific antigen response rate (decline >/=50%

266 Prostate-specific antigen response rate to enzalutamide

267 Exploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab

268 d increases in progression-free survival and prostate-specific antigen response rates suggest antitum

269 The initial prostate-specific antigen response showed no correlation

270 checked every 2 wk by laboratory tests, the prostate-specific antigen response was checked every 4 w

271 Prostate-specific antigen responses to ipilimumab were a

272 Prostate-specific antigen responses were achieved in bot

273 rho = 0.64; PSMA expression, rho = 0.47; and prostate-specific antigen, rho = 0.52).

274 BCR was defined as 2 consecutive prostate-specific antigen rises of at least 0.2 ng/mL.

275 Studies demonstrate that use of prostate-specific antigen screening decreased significan

276 s Task Force (USPSTF) recommendation against prostate-specific antigen screening in 2012.

277 Among a subcohort of men receiving regular prostate-specific antigen screening, the association wit

278 commendation against routine population-wide prostate-specific antigen screening.

279 nding on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytol

280 xpression of clinical markers such as Ki-67, prostate specific antigen, synaptophysin, CD31, and CD56

281 Prostate-specific antigen targeting is likely to enhance

282 uld not screen for prostate cancer using the prostate-specific antigen test in average-risk men under

283 uld not screen for prostate cancer using the prostate-specific antigen test in patients who do not ex

284 sion to screen for prostate cancer using the prostate-specific antigen test on the risk for prostate

285 Prostate-specific antigen testing every 4 to 6 months is

286 nced or fatal prostate cancer, regardless of prostate-specific antigen testing status.

287 Active surveillance protocols should include prostate-specific antigen testing, digital rectal examin

288 Among men who reported a history of prostate-specific antigen testing, high HEI-2005 and AHE

289 Mammography, prostate-specific antigen testing, or fecal immunochemic

290 and were inversely correlated with levels of prostate-specific antigen, the main prognostic factor in

291 The Chip EIA device was used to assay total prostate specific antigen (tPSA) in 19 serum samples.

292 ibits the expression of AR and its effectors prostate-specific antigen, transmembrane protease serine

293 onal level) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stag

294 Men with high serum prostate specific antigen usually undergo transrectal ul

295 61 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-

296 0.76 and 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, res

297 l recurrence after primary treatment (median prostate-specific antigen values obtained at the time of

298 ously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184).

299 ne is designed to induce T-cell responses to prostate-specific antigen, we demonstrate that this vacc

300 In multivariable analysis, GC and pre-RP prostate-specific antigen were independent predictors of